MAP2K7 and hepatocellular carcinoma: Sorafenib is a Raf1 / Mek / Erk kinase inhibitor used to treat hepatocellular carcinoma (Adjibade et al., 2015), thyroid carcinoma (Lin et al., 2021), and renal carcinoma (Chen W. et al., 2018).